1.4 Pharmacological effects of human insulin and synthetic insulin analogues The aim of optimal insulin therapy in diabetes mellitus is to simulate the control of glucose metabolism in plasma in endogenous hormone secretion as naturally as possible. Normal-acting recombinant human insulin is present in ...
Due to these pharmacological properties, it has been suggested that this type of insulin may have a role in facilitating the transition from continuous intravenous insulin infusion to subcutaneous maintenance therapy in patients with DKA. In one trial the authors hypothesized that the initiation of a...
Phase 1 trials for BioChaperone Lispro are equally encouraging with phase 3 trials yet to be initiated. Comparative analysis of the clinical and pharmacological evidence for these new prandial insulin candidates in the treatment of type 1 and type 2 diabetes is the main focus of this review.doi:...
Another pharmacological property ofIDegis that it can be combined with the rapid-acting insulin analogue IAsp without altering the properties of either of the components. Insulin degludec/insulin aspart(IDegAsp), comprised of 70% IDeg and 30% IAsp, is the first soluble insulin combination product ...
The robust effects of GLP-1 RAs to reduce body weight, usually by 2–7 kg (or % of initial body weight) on average in type 2 diabetes, have led to the exploration of GLP-1 RAs as a novel pharmacological treatment in obese but non-diabetic subjects often withimpaired fasting glucoseorgl...